Health News

Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study was initiated in major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events.

Read more

Filed under: Pharmacy News
Tags: Genetic, Pharmacy

Related posts

• Warning From AMP About Direct Access Genetic Testing (0)
  In response to recent announcements about consumer genetic tests being made available in retail drugstores, the Association for Molecular Pathology (AMP) today reiterated its position that these tests should be provided to the public only through the services of appropriate health care professionals that order tests from laboratories that are certified by CLIA for highcomplexity [...]
  
  
• Walgreens Shelves OTC Genetic Tests (0)
  Pharmacy giant Walgreens has decided to hold off on selling Pathway Genomics' home genetic testing kit after the FDA sent the kit manufacturer a letter warning that the tests were not federally approved. Read more [tags] General Health News [/tags]
  
  
• VUMC doctors to begin statin drug screening for rare genetic variation (0)
  Vanderbilt University Medical Center doctors announced today they will begin screening patients who take commonly prescribed statin drugs for a rare genetic variation that can increase risks for side effects from these drugs such as muscle aches, kidney damage and even death. Read more [tags] Pharmacy News [/tags]
  
  
• Viral Genetics: Company update (0)
  Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer [...]
  
  
• Viral Genetics Updates HIV/AIDS And Drug Resistant Cancer Research Programs (0)
  Viral Genetics, Inc. (Pinksheets: VRAL) continues to make the transition to a clinical-stage company. The Company's two lead pharmaceutical programs -- APi1177 for HIV/AIDS, and various Metabolic Disruption (MDT) compounds for drug-resistant cancers -- are being advanced towards clinical development under sponsor- or investigator-initiated Investigational New Drug (IND) pathways... Read more [tags] Pharmacy News [/tags]